Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer's Disease

被引:242
作者
Chen, Rongqing [1 ]
Zhang, Jian [1 ]
Wu, Yan [1 ]
Wang, Dongqing [3 ,4 ]
Feng, Guoping [3 ,4 ]
Tang, Ya-Ping [2 ]
Teng, Zhaoqian [1 ]
Chen, Chu [1 ]
机构
[1] Louisiana State Univ, Hlth New Orleans Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA
[2] Louisiana State Univ, Hlth New Orleans Sci Ctr, Sch Med, Dept Anat & Cell Biol, New Orleans, LA 70112 USA
[3] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA
[4] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA
关键词
ENDOCANNABINOID; 2-ARACHIDONOYLGLYCEROL; TRANSGENIC MICE; CANNABINOID RECEPTORS; SYNAPTIC PLASTICITY; MEMORY; EXPRESSION; NEURONS; NEUROINFLAMMATION; ACCUMULATION; TRANSMISSION;
D O I
10.1016/j.celrep.2012.09.030
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Alzheimer's disease (AD) is the most common cause of dementia among older people. There are no effective medications currently available to prevent and treat AD and halt disease progression. Monoacylglycerol lipase (MAGL) is the primary enzyme metabolizing the endocannabinoid 2-arachidonoylglycerol in the brain. We show here that inactivation of MAGL robustly suppressed production and accumulation of beta-amyloid (A beta) associated with reduced expression of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) in a mouse model of AD. MAGL inhibition also prevented neuroinflammation, decreased neurodegeneration, maintained integrity of hippocampal synaptic structure and function, and improved long-term synaptic plasticity, spatial learning, and memory in AD animals. Although the molecular mechanisms underlying the beneficial effects produced by MAGL inhibition remain to be determined, our results suggest that MAGL, which regulates endocannabinoid and prostaglandin signaling, contributes to pathogenesis and neuropathology of AD, and thus is a promising therapeutic target for the prevention and treatment of AD.
引用
收藏
页码:1329 / 1339
页数:11
相关论文
共 55 条
[1]
Alger BE, 2009, CURR TOP BEHAV NEURO, V1, P141, DOI 10.1007/978-3-540-88955-7_6
[2]
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses [J].
Almeida, CG ;
Tampellini, D ;
Takahashi, RH ;
Greengard, P ;
Lin, MT ;
Snyder, EM ;
Gouras, GK .
NEUROBIOLOGY OF DISEASE, 2005, 20 (02) :187-198
[3]
The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury [J].
Arevalo-Martin, Angel ;
Garcia-Ovejero, Daniel ;
Molina-Holgado, Eduardo .
NEUROBIOLOGY OF DISEASE, 2010, 38 (02) :304-312
[4]
Probing the Biology of Alzheimer's Disease in Mice [J].
Ashe, Karen H. ;
Zahs, Kathleen R. .
NEURON, 2010, 66 (05) :631-645
[5]
Cortical plasticity in Alzheimer's disease in humans and rodents [J].
Battaglia, Fortunato ;
Wang, Hoau-Yan ;
Ghilardi, M. Felice ;
Gashi, Eleonora ;
Quartarone, Angelo ;
Friedman, Eitan ;
Nixon, Ralph A. .
BIOLOGICAL PSYCHIATRY, 2007, 62 (12) :1405-1412
[6]
Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders [J].
Bisogno, Tiziana ;
Di Marzo, Vincenzo .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (05) :564-573
[7]
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol [J].
Blankman, Jacqueline L. ;
Simon, Gabriel M. ;
Cravatt, Benjamin F. .
CHEMISTRY & BIOLOGY, 2007, 14 (12) :1347-1356
[8]
The endocannabinoid system in targeting inflammatory neurodegenerative diseases [J].
Centonze, Diego ;
Finazzi-Agro, Alessandro ;
Bernardi, Giorgio ;
Maccarrone, Mauro .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (04) :180-187
[9]
Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity [J].
Chen, C ;
Magee, JC ;
Bazan, NG .
JOURNAL OF NEUROPHYSIOLOGY, 2002, 87 (06) :2851-2857
[10]
ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL PROTECTS NEURONS AGAINST β-AMYLOID INSULTS [J].
Chen, X. ;
Zhang, J. ;
Chen, C. .
NEUROSCIENCE, 2011, 178 :159-168